Details of the Drug Combinations

General Information of This Drug (ID: DM4O2Z7)

Drug Name
Cyclophosphamide   DM4O2Z7
Synonyms
ASTA; Ciclofosfamida; Ciclophosphamide; Clafen; Claphene; Cycloblastin; Cyclophosphamid; Cyclophosphamides; Cyclophosphamidum; Cyclophosphan; Cyclophosphane; Cyclophosphanum; Cyclophosphoramide; Cyclostin; Cyklofosfamid; Cytophosphan; Cytophosphane; Cytoxan; Endoxan; Endoxana; Endoxanal; Endoxane; Enduxan; Genoxal; Mitoxan; Neosar; Procytox; Revimmune; Semdoxan; Sendoxan; Senduxan; Zyklophosphamid; Ciclophosphamide [INN]; Cyclophosphamide Sterile; Cyclophosphamide anhydrous; Cyklofosfamid [Czech]; Cytoxan Lyoph; Endoxan R; Lyophilized Cytoxan; Zyklophosphamid [German]; ASTA B518; Asta B 518; B 518; C 0768; CB 4564; SK 20501; B-518; CB-4564; Ciclofosfamida [INN-Spanish]; Cyclophosphamide (INN); Cyclophosphamide (TN); Cyclophosphamide (anhydrous form); Cyclophosphamide (anhydrous); Cyclophosphamidum [INN-Latin]; Cytoxan (TN); Endoxan (TN); Endoxan-Asta; Neosar (TN); Occupation, cyclophosphamide exposure; Procytox (TN); Revimmune (TN); Bis(2-Chloroethyl)phosphami de cyclic propanolamide; Bis(2-Chloroethyl)phosphamide cyclic propanolamide ester; Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester; D,L-Cyclophosphamide; Cyclophosphamide, (+-)-Isomer; N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide; (+-)-Cyclophosphamide; (-)-Cyclophosphamide; (RS)-Cyclophosphamide; 1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine; 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin; 4-Hydroxy-cyclophosphan-mamophosphatide
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Central nervous system neoplasm N.A. Approved [1]
Glioblastoma 2A00 Approved [1]
Immunodeficiency 4A00-4A85 Approved [1]
Inflammatory breast cancer 2C62 Approved [1]
Lupus nephritis 4A40.0Y Approved [1]
Lymphoma 2A80-2A86 Approved [1]
Multiple sclerosis 8A40 Approved [1]
Mycosis fungoides 2B01 Approved [1]
Plasma cell myeloma 2A83.1 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Classic Hodgkin lymphoma N.A. Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
Retinoblastoma 2D02.2 Investigative [1]
Scleroderma 4A42 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

412 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Cyclophosphamide DCOP0YV ABIRATERONE Clear cell renal cell carcinoma (Cell Line: A498) [3]
ABIRATERONE + Cyclophosphamide DC9WC0B ABIRATERONE Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Altretamine + Cyclophosphamide DCLE51F Altretamine Adenocarcinoma (Cell Line: SW-620) [3]
Altretamine + Cyclophosphamide DCPUQFC Altretamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Altretamine + Cyclophosphamide DCTANBS Altretamine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Aminolevulinic Acid Hydrochloride + Cyclophosphamide DCWTNWI Aminolevulinic Acid Hydrochloride Glioma (Cell Line: SF-539) [3]
Aminolevulinic Acid Hydrochloride + Cyclophosphamide DCFB6XR Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: HCT-15) [4]
Anastrozole + Cyclophosphamide DCRXW7O Anastrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Bendamustine hydrochloride + Cyclophosphamide DCVMRUX Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Bendamustine hydrochloride + Cyclophosphamide DC3AO5V Bendamustine hydrochloride Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Bendamustine hydrochloride + Cyclophosphamide DCF4MVO Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: HS 578T) [5]
BIO-300 + Cyclophosphamide DCWVAMX BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [3]
Bleomycin + Cyclophosphamide DCTB140 Bleomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Bleomycin + Cyclophosphamide DCVXTF3 Bleomycin Melanoma (Cell Line: UACC-257) [4]
Busulfan + Cyclophosphamide DCTQWWZ Busulfan Adenocarcinoma (Cell Line: HCC-2998) [3]
Busulfan + Cyclophosphamide DC8B7U9 Busulfan Adenocarcinoma (Cell Line: HT29) [3]
Crizotinib + Cyclophosphamide DCFU2H6 Crizotinib Carcinoma (Cell Line: RXF 393) [5]
Cyclophosphamide + Pentostatin DC5FEHQ Pentostatin Astrocytoma (Cell Line: SNB-19) [3]
Cyclophosphamide + Pentostatin DC7SSQ0 Pentostatin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cyclophosphamide + Pentostatin DCPFA1Y Pentostatin Glioma (Cell Line: SF-295) [3]
Cyclophosphamide + Pentostatin DC4ZXCG Pentostatin Glioma (Cell Line: SF-268) [3]
Cyclophosphamide + PD-0325901 DC1XCHL PD-0325901 Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + PD-0325901 DCUJZ4V PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + PD-0325901 DCALC5U PD-0325901 Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + Ixabepilone DC6VRXG Ixabepilone Adenocarcinoma (Cell Line: A549) [3]
Cyclophosphamide + Ixabepilone DC0D39J Ixabepilone Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + Ixabepilone DCBIZ4I Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Cyclophosphamide + Ixabepilone DCYC2XV Ixabepilone Melanoma (Cell Line: MALME-3M) [3]
Cyclophosphamide + Lapatinib DCGSNI4 Lapatinib Germ cell tumour (Cell Line: PA1) [3]
Cyclophosphamide + Lapatinib DCG6AF4 Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cyclophosphamide + Lapatinib DCCILOS Lapatinib Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + MK-1775 DCN4OAO MK-1775 Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + MK-1775 DCNEQCX MK-1775 Adenocarcinoma (Cell Line: NCIH1650) [3]
Cyclophosphamide + MK-1775 DCT3617 MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + MK-1775 DCM5RPR MK-1775 Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + MK-1775 DCESAQK MK-1775 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + SCH-900776 DCOBJOZ SCH-900776 Adenocarcinoma (Cell Line: SW-620) [3]
Cyclophosphamide + SNX-2112 DC739CL SNX-2112 Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + SNX-2112 DCUCV4G SNX-2112 Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + SCH 727965 DCPP1TD SCH 727965 Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + SCH 727965 DC4XGB7 SCH 727965 Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + SCH 727965 DCFVBCO SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + Erlotinib DCCZDGF Erlotinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Cyclophosphamide + Ifosfamide DCNXQ72 Ifosfamide Adenocarcinoma (Cell Line: NCIH23) [3]
Cyclophosphamide + Ifosfamide DC0CBTH Ifosfamide Adenocarcinoma (Cell Line: A549) [3]
Cyclophosphamide + Ifosfamide DCO6I23 Ifosfamide Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + Ifosfamide DCWKYRI Ifosfamide Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + Ifosfamide DCKIPGE Ifosfamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cyclophosphamide + Ifosfamide DCIPPO8 Ifosfamide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Cyclophosphamide + Ifosfamide DCWTZ82 Ifosfamide Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Cyclophosphamide + Ifosfamide DC3SLXE Ifosfamide Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cyclophosphamide + Ifosfamide DC7S7Z1 Ifosfamide Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cyclophosphamide + Ifosfamide DCZ0JUE Ifosfamide Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Cyclophosphamide + Ifosfamide DCFNU74 Ifosfamide Glioma (Cell Line: SF-295) [3]
Cyclophosphamide + Ifosfamide DCY1AFS Ifosfamide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [3]
Cyclophosphamide + Ifosfamide DC3KMH5 Ifosfamide Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cyclophosphamide + Ifosfamide DCIKZP7 Ifosfamide Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Cyclophosphamide + Ifosfamide DC2FO8C Ifosfamide Malignant melanoma (Cell Line: LOX IMVI) [3]
Cyclophosphamide + Ifosfamide DCW1A6L Ifosfamide Melanoma (Cell Line: SK-MEL-2) [3]
Cyclophosphamide + MK-5108 DCQVX3U MK-5108 Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + MK-5108 DCO7ST1 MK-5108 Malignant melanoma (Cell Line: HT144) [3]
Cyclophosphamide + MK-5108 DCLZQHY MK-5108 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + Mitomycin DCTJLJN Mitomycin Adenocarcinoma (Cell Line: DU-145) [3]
Cyclophosphamide + Mitomycin DC8MYKM Mitomycin Adenocarcinoma (Cell Line: HCT-15) [3]
Cyclophosphamide + Mitomycin DCA1AUG Mitomycin Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + Mitomycin DCEM8KN Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Cyclophosphamide + Mitomycin DC0HWYR Mitomycin Astrocytoma (Cell Line: SNB-19) [3]
Cyclophosphamide + Mitomycin DC562JO Mitomycin Glioma (Cell Line: SF-268) [3]
Cyclophosphamide + Mitomycin DCZH66Q Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cyclophosphamide + Mitomycin DCZ3C7P Mitomycin Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cyclophosphamide + Mitomycin DCBF60V Mitomycin Melanoma (Cell Line: SK-MEL-2) [3]
Cyclophosphamide + Mitomycin DC7FFR6 Mitomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Cyclophosphamide + MK-4827 DC2Z6AF MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + MK-4827 DC0Q2FE MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + MK-4827 DCZT0MV MK-4827 Adenocarcinoma (Cell Line: DLD1) [3]
Cyclophosphamide + MK-4827 DCX9SO9 MK-4827 Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + MK-4827 DCWJRIV MK-4827 Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + MK-4827 DCL4QID MK-4827 Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + MK-4827 DCSH8PT MK-4827 Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + MK-4827 DCOYS1O MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + Idarubicin DC1HI6P Idarubicin Adenocarcinoma (Cell Line: CAOV3) [3]
Cyclophosphamide + Idarubicin DC41ESM Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + Idarubicin DCKPPQ2 Idarubicin Adenocarcinoma (Cell Line: A427) [3]
Cyclophosphamide + Idarubicin DCVFZEH Idarubicin Adenocarcinoma (Cell Line: NCIH2122) [3]
Cyclophosphamide + Idarubicin DCE5ETU Idarubicin Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + Idarubicin DC5GU7Z Idarubicin Adenocarcinoma (Cell Line: DLD1) [3]
Cyclophosphamide + Idarubicin DCWHO5J Idarubicin Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + Idarubicin DCZ16T5 Idarubicin Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + Idarubicin DCHCUG5 Idarubicin Amelanotic melanoma (Cell Line: A2058) [3]
Cyclophosphamide + Idarubicin DC7RJ1Y Idarubicin Germ cell tumour (Cell Line: PA1) [3]
Cyclophosphamide + Idarubicin DCM2OSN Idarubicin Glioblastoma? (Cell Line: T98G) [3]
Cyclophosphamide + Idarubicin DCRJ3K8 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Cyclophosphamide + Idarubicin DCEO0XD Idarubicin Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + Idarubicin DCSBJFK Idarubicin Malignant melanoma (Cell Line: HT144) [3]
Cyclophosphamide + Idarubicin DC8KC3T Idarubicin Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + Idarubicin DC4B3AX Idarubicin Malignant melanoma (Cell Line: UACC62) [3]
Cyclophosphamide + Idarubicin DCJ4VV8 Idarubicin Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + Idarubicin DCPUSBN Idarubicin Mesothelioma (Cell Line: MSTO) [3]
Cyclophosphamide + Idarubicin DCPCDLA Idarubicin Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + Idarubicin DC93USR Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Cyclophosphamide + Idarubicin DCLRQFN Idarubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + Idarubicin DCUK17Z Idarubicin Prostate carcinoma (Cell Line: LNCAP) [3]
Cyclophosphamide + Idarubicin DCE7XAP Idarubicin Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + GSK525762 DC8N6ML GSK525762 Adenocarcinoma (Cell Line: CAOV3) [3]
Cyclophosphamide + GSK525762 DCW0HBZ GSK525762 Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + GSK525762 DCWFR0P GSK525762 Adenocarcinoma (Cell Line: NCIH23) [3]
Cyclophosphamide + GSK525762 DCDLW1R GSK525762 Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + GSK525762 DC52LO2 GSK525762 Adenocarcinoma (Cell Line: DLD1) [3]
Cyclophosphamide + GSK525762 DCNST3U GSK525762 Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + GSK525762 DC90KSO GSK525762 Adenocarcinoma (Cell Line: SW-620) [3]
Cyclophosphamide + GSK525762 DCHIK3X GSK525762 Amelanotic melanoma (Cell Line: A2058) [3]
Cyclophosphamide + GSK525762 DCP4AFR GSK525762 Germ cell tumour (Cell Line: PA1) [3]
Cyclophosphamide + GSK525762 DCRZKG5 GSK525762 Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + GSK525762 DCUG23R GSK525762 Malignant melanoma (Cell Line: HT144) [3]
Cyclophosphamide + GSK525762 DC4PABF GSK525762 Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + GSK525762 DCDEZAZ GSK525762 Malignant melanoma (Cell Line: UACC62) [3]
Cyclophosphamide + GSK525762 DCR68SZ GSK525762 Malignant melanoma (Cell Line: RPMI7951) [3]
Cyclophosphamide + GSK525762 DCIBAAN GSK525762 Mesothelioma (Cell Line: MSTO) [3]
Cyclophosphamide + GSK525762 DCSTLWI GSK525762 Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + GSK525762 DCHE0HO GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Cyclophosphamide + GSK525762 DCKQARG GSK525762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + GSK525762 DCYCQU1 GSK525762 Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + Chlorambucil DCEMLR7 Chlorambucil Adenocarcinoma (Cell Line: HT29) [3]
Cyclophosphamide + Chlorambucil DCE7LFI Chlorambucil Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Cyclophosphamide + Chlorambucil DCRNV0K Chlorambucil Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cyclophosphamide + Chlorambucil DCLUICT Chlorambucil Lung adenocarcinoma (Cell Line: MDA-MB-231) [3]
Cyclophosphamide + Chlorambucil DCIK8CD Chlorambucil Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Cyclophosphamide + Sorafenib DCURLEA Sorafenib Adenocarcinoma (Cell Line: OVCAR3) [3]
Cyclophosphamide + Sorafenib DCSZ9U7 Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [3]
Cyclophosphamide + Sorafenib DCZ51HE Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cyclophosphamide + ER819762 DCK6QPI ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [3]
Cyclophosphamide + MK-2206 DC7MMDQ MK-2206 Adenocarcinoma (Cell Line: HCT116) [3]
Cyclophosphamide + MK-2206 DCFMVY0 MK-2206 Malignant melanoma (Cell Line: A375) [3]
Cyclophosphamide + MK-2206 DCLVZN6 MK-2206 Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + Dasatinib DCAZ3FI Dasatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Cyclophosphamide + Dasatinib DCEM6O5 Dasatinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Cyclophosphamide + Dasatinib DC6VOZT Dasatinib Adenocarcinoma (Cell Line: SW-620) [3]
Cyclophosphamide + Dasatinib DC9NQ49 Dasatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Cyclophosphamide + Dasatinib DC2AFQV Dasatinib Malignant melanoma (Cell Line: SKMEL30) [3]
Cyclophosphamide + Dasatinib DC37J6G Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Cyclophosphamide + Dasatinib DCD4ZWN Dasatinib Prostate carcinoma (Cell Line: VCAP) [3]
Cyclophosphamide + Pentostatin DCM8QX4 Pentostatin Carcinoma (Cell Line: MCF7) [5]
Cyclophosphamide + Pentostatin DCEMF87 Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Cyclophosphamide + PD-0325901 DCZK2XQ PD-0325901 Breast carcinoma (Cell Line: KPL1) [5]
Cyclophosphamide + PD-0325901 DCMMSMM PD-0325901 Carcinoma (Cell Line: EFM192B) [5]
Cyclophosphamide + PD-0325901 DC7NZZJ PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + Ixabepilone DC02HYN Ixabepilone Colon adenocarcinoma (Cell Line: COLO 205) [5]
Cyclophosphamide + Ixabepilone DC5HF60 Ixabepilone Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + MK-1775 DC9XN22 MK-1775 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Cyclophosphamide + SCH-900776 DCK9EJ2 SCH-900776 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + SNX-2112 DCQ53M6 SNX-2112 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Cyclophosphamide + SCH 727965 DCNZWET SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [5]
Cyclophosphamide + SCH 727965 DC146CU SCH 727965 Carcinoma (Cell Line: OV90) [5]
Cyclophosphamide + SCH 727965 DCSD09J SCH 727965 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + Erlotinib DC2XMT0 Erlotinib Breast carcinoma (Cell Line: ZR751) [5]
Cyclophosphamide + Ifosfamide DCMOIEM Ifosfamide Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Cyclophosphamide + Ifosfamide DCZAMKO Ifosfamide Colon adenocarcinoma (Cell Line: COLO 205) [5]
Cyclophosphamide + Ifosfamide DC9IF58 Ifosfamide Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Cyclophosphamide + MK-5108 DC5UPE0 MK-5108 Colon carcinoma (Cell Line: RKO) [5]
Cyclophosphamide + MK-5108 DCC43RE MK-5108 Rectal adenocarcinoma (Cell Line: SW837) [5]
Cyclophosphamide + Mitomycin DCDK21F Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Cyclophosphamide + MK-4827 DCFMAJ3 MK-4827 Colon carcinoma (Cell Line: RKO) [5]
Cyclophosphamide + Idarubicin DCJ36KA Idarubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [5]
Cyclophosphamide + Idarubicin DC1H24L Idarubicin Breast carcinoma (Cell Line: ZR751) [5]
Cyclophosphamide + Idarubicin DCM4YTV Idarubicin Breast carcinoma (Cell Line: KPL1) [5]
Cyclophosphamide + Idarubicin DCQWQHL Idarubicin Breast carcinoma (Cell Line: OCUBM) [5]
Cyclophosphamide + Idarubicin DCWVL11 Idarubicin Carcinoma (Cell Line: EFM192B) [5]
Cyclophosphamide + Idarubicin DC5989Y Idarubicin Carcinoma (Cell Line: MDAMB436) [5]
Cyclophosphamide + Idarubicin DC1GROU Idarubicin Colon adenocarcinoma (Cell Line: LOVO) [5]
Cyclophosphamide + Idarubicin DCSKXS9 Idarubicin Colon carcinoma (Cell Line: RKO) [5]
Cyclophosphamide + Idarubicin DCW2U0C Idarubicin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + Bortezomib DCK0JWJ Bortezomib Rectal adenocarcinoma (Cell Line: SW837) [5]
Cyclophosphamide + GSK525762 DCNW7PM GSK525762 Breast carcinoma (Cell Line: OCUBM) [5]
Cyclophosphamide + GSK525762 DCISQRC GSK525762 Carcinoma (Cell Line: EFM192B) [5]
Cyclophosphamide + GSK525762 DCFG1PG GSK525762 Colon adenocarcinoma (Cell Line: LOVO) [5]
Cyclophosphamide + GSK525762 DCWE5TX GSK525762 Colon carcinoma (Cell Line: RKO) [5]
Cyclophosphamide + GSK525762 DCV3H7K GSK525762 Invasive ductal carcinoma (Cell Line: T-47D) [5]
Cyclophosphamide + Chlorambucil DCECI0G Chlorambucil Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Cyclophosphamide + Sorafenib DCWQE9R Sorafenib Breast carcinoma (Cell Line: ZR751) [5]
Cyclophosphamide + MK-2206 DCLP3XA MK-2206 Breast carcinoma (Cell Line: KPL1) [5]
Cyclophosphamide + MK-2206 DCPO1W1 MK-2206 Colon carcinoma (Cell Line: RKO) [5]
Cyclophosphamide + Dasatinib DC5WTCJ Dasatinib Breast carcinoma (Cell Line: ZR751) [5]
Cyclophosphamide + Dasatinib DC4F547 Dasatinib Carcinoma (Cell Line: EFM192B) [5]
Dacarbazine + Cyclophosphamide DC2O3AY Dacarbazine Adenocarcinoma (Cell Line: SW-620) [3]
Dacarbazine + Cyclophosphamide DCD593I Dacarbazine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Dacarbazine + Cyclophosphamide DCN5G3C Dacarbazine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dactinomycin + Cyclophosphamide DCEQJ2S Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Dactinomycin + Cyclophosphamide DC390HX Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Dasatinib + Cyclophosphamide DCGPRW4 Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Dasatinib + Cyclophosphamide DCYQILW Dasatinib Adenocarcinoma (Cell Line: HCT116) [3]
Dasatinib + Cyclophosphamide DCKRR63 Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-5) [3]
Dasatinib + Cyclophosphamide DC39K6V Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Dasatinib + Cyclophosphamide DCG6J7C Dasatinib Melanoma (Cell Line: UACC-257) [3]
Dasatinib + Cyclophosphamide DCCBYFQ Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Dexrazoxane + Cyclophosphamide DCTTHOU Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Dexrazoxane + Cyclophosphamide DC43YBL Dexrazoxane Invasive ductal carcinoma (Cell Line: BT-549) [5]
Dexrazoxane + Cyclophosphamide DCL1KT5 Dexrazoxane Adenocarcinoma (Cell Line: HCT116) [4]
DFN-15 + Cyclophosphamide DCBUUV2 DFN-15 Chronic myelogenous leukemia (Cell Line: K-562) [3]
DFN-15 + Cyclophosphamide DCADQ51 DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
DFN-15 + Cyclophosphamide DC8T5P6 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
DFN-15 + Cyclophosphamide DC948YS DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Digitoxin + Cyclophosphamide DCZAXNO Digitoxin Glioma (Cell Line: SF-539) [3]
Digitoxin + Cyclophosphamide DCRIRDJ Digitoxin Carcinoma (Cell Line: MCF7) [5]
Docetaxel + Cyclophosphamide DC0S7OE Docetaxel Adenocarcinoma (Cell Line: DU-145) [3]
Docetaxel + Cyclophosphamide DC57EOD Docetaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Docetaxel + Cyclophosphamide DC1WKXV Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Docetaxel + Cyclophosphamide DC612QV Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Docetaxel + Cyclophosphamide DCFH08P Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [5]
Epirubicin + Cyclophosphamide DC68VB0 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Cyclophosphamide DC3OQEU Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Epirubicin + Cyclophosphamide DC0JQYI Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [3]
Epirubicin + Cyclophosphamide DCFDQ9I Epirubicin Carcinoma (Cell Line: RXF 393) [5]
Epirubicin + Cyclophosphamide DCG0369 Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [5]
Epirubicin + Cyclophosphamide DCJEQRG Epirubicin Adenocarcinoma (Cell Line: HCT-15) [4]
Epirubicin + Cyclophosphamide DCIAOL6 Epirubicin Amelanotic melanoma (Cell Line: M14) [4]
Epirubicin + Cyclophosphamide DC0D43T Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [4]
Epirubicin + Cyclophosphamide DC0WB3Q Epirubicin Malignant melanoma (Cell Line: UACC62) [4]
Epirubicin + Cyclophosphamide DCGJEEH Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Estramustine + Cyclophosphamide DCABTWY Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [3]
Estramustine + Cyclophosphamide DCBB37K Estramustine Adenocarcinoma (Cell Line: OVCAR3) [4]
Estramustine + Cyclophosphamide DCX5BFU Estramustine Adenocarcinoma (Cell Line: HCT116) [4]
Fludarabine + Cyclophosphamide DCM0FDQ Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Fluorouracil + Cyclophosphamide DCGX3V1 Fluorouracil Adenocarcinoma (Cell Line: OVCAR3) [4]
Fluorouracil + Cyclophosphamide DC0YQ4U Fluorouracil Adenocarcinoma (Cell Line: SW-620) [4]
Fluorouracil + Cyclophosphamide DC7V6VG Fluorouracil Amelanotic melanoma (Cell Line: A2058) [4]
Fluorouracil + Cyclophosphamide DCK7825 Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [4]
Fluorouracil + Cyclophosphamide DCF32CP Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
FORMESTANE + Cyclophosphamide DCIB2CV FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [3]
FORMESTANE + Cyclophosphamide DCSFSPW FORMESTANE Astrocytoma (Cell Line: U251) [3]
FORMESTANE + Cyclophosphamide DC9UU9J FORMESTANE Glioma (Cell Line: SF-268) [3]
FORMESTANE + Cyclophosphamide DC4L9M8 FORMESTANE Lung adenocarcinoma (Cell Line: HOP-62) [3]
FORMESTANE + Cyclophosphamide DCFDU02 FORMESTANE Malignant melanoma (Cell Line: UACC62) [3]
FORMESTANE + Cyclophosphamide DCPSM29 FORMESTANE Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
FORMESTANE + Cyclophosphamide DCIKUF4 FORMESTANE Invasive ductal carcinoma (Cell Line: BT-549) [5]
FORMESTANE + Cyclophosphamide DC56VIZ FORMESTANE Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Fulvestrant + Cyclophosphamide DCRBQ9A Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [3]
Fulvestrant + Cyclophosphamide DCRD17D Fulvestrant Adenocarcinoma (Cell Line: HT29) [3]
Fulvestrant + Cyclophosphamide DCKKHKK Fulvestrant Malignant melanoma (Cell Line: UACC62) [3]
Fulvestrant + Cyclophosphamide DCRJMWD Fulvestrant Melanoma (Cell Line: MALME-3M) [3]
Fulvestrant + Cyclophosphamide DCXNDI2 Fulvestrant Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Fulvestrant + Cyclophosphamide DCL8EC5 Fulvestrant Prostate carcinoma (Cell Line: PC-3) [3]
Gefitinib + Cyclophosphamide DC3TZAV Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Hepzato + Cyclophosphamide DCBXQWO Hepzato Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Hepzato + Cyclophosphamide DCBTDB9 Hepzato Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Hepzato + Cyclophosphamide DCHR3XV Hepzato Lung adenocarcinoma (Cell Line: HOP-62) [4]
Hepzato + Cyclophosphamide DCK9A7U Hepzato Malignant melanoma (Cell Line: UACC62) [4]
Idarubicin + Cyclophosphamide DCBRGVD Idarubicin Glioma (Cell Line: SF-539) [3]
Idarubicin + Cyclophosphamide DCAWVDV Idarubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Idarubicin + Cyclophosphamide DCRKTG1 Idarubicin Adenocarcinoma (Cell Line: OVCAR3) [4]
Idarubicin + Cyclophosphamide DCIFA5M Idarubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Imatinib + Cyclophosphamide DCX0419 Imatinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Imatinib + Cyclophosphamide DCT4V4E Imatinib Adenocarcinoma (Cell Line: HCT116) [3]
Imatinib + Cyclophosphamide DC4H7IS Imatinib Adenocarcinoma (Cell Line: HCT-15) [3]
Imatinib + Cyclophosphamide DCOKVMI Imatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Imatinib + Cyclophosphamide DCWTDXQ Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Imatinib + Cyclophosphamide DC6P32I Imatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [3]
Imatinib + Cyclophosphamide DCRQQ91 Imatinib Malignant melanoma (Cell Line: LOX IMVI) [3]
Imatinib + Cyclophosphamide DCVEFNH Imatinib Melanoma (Cell Line: UACC-257) [3]
Imatinib + Cyclophosphamide DCHENJJ Imatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Imatinib + Cyclophosphamide DCHPNQP Imatinib Colon carcinoma (Cell Line: KM12) [5]
Indazole derivative 5 + Cyclophosphamide DCV4TI9 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Indazole derivative 5 + Cyclophosphamide DCOGOBF Indazole derivative 5 Renal cell carcinoma (Cell Line: UO-31) [3]
Indazole derivative 5 + Cyclophosphamide DCQ9PLO Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Indazole derivative 5 + Cyclophosphamide DCZLJBT Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Indazole derivative 5 + Cyclophosphamide DCIQPJB Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Isoniazid + Cyclophosphamide DCAMQD0 Isoniazid Adenocarcinoma (Cell Line: DU-145) [3]
Isoniazid + Cyclophosphamide DCXJ6N0 Isoniazid Adenocarcinoma (Cell Line: HT29) [3]
Isoniazid + Cyclophosphamide DC5JYUE Isoniazid Adenocarcinoma (Cell Line: SW-620) [3]
Isoniazid + Cyclophosphamide DCXXH9S Isoniazid Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Isoniazid + Cyclophosphamide DCIAO1R Isoniazid Amelanotic melanoma (Cell Line: MDA-MB-435) [3]
Isoniazid + Cyclophosphamide DCHYU0G Isoniazid High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [3]
Isoniazid + Cyclophosphamide DCL8UCE Isoniazid Lung adenocarcinoma (Cell Line: HOP-62) [3]
Isoniazid + Cyclophosphamide DCSSP36 Isoniazid Malignant melanoma (Cell Line: UACC62) [3]
Isoniazid + Cyclophosphamide DCMTQG8 Isoniazid Renal cell carcinoma (Cell Line: UO-31) [3]
Lapatinib + Cyclophosphamide DCF25SR Lapatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Lapatinib + Cyclophosphamide DCPQE5Y Lapatinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Lapatinib + Cyclophosphamide DCC2WFR Lapatinib Astrocytoma (Cell Line: SNB-19) [4]
Lapatinib + Cyclophosphamide DCNLHG6 Lapatinib Glioma (Cell Line: SF-539) [4]
Lapatinib + Cyclophosphamide DCXV3R2 Lapatinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Lapatinib + Cyclophosphamide DCWDMNV Lapatinib Malignant melanoma (Cell Line: UACC62) [4]
Lapatinib + Cyclophosphamide DCNKUFW Lapatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Lenalidomide + Cyclophosphamide DCYJA5F Lenalidomide Glioma (Cell Line: SF-268) [3]
Lenalidomide + Cyclophosphamide DCV19Y5 Lenalidomide Glioma (Cell Line: SF-539) [3]
Lenalidomide + Cyclophosphamide DCM1CNO Lenalidomide Carcinoma (Cell Line: RXF 393) [5]
Lenalidomide + Cyclophosphamide DCQAHLQ Lenalidomide Adenocarcinoma (Cell Line: OVCAR3) [4]
Lenalidomide + Cyclophosphamide DCDB4X1 Lenalidomide Adenocarcinoma (Cell Line: HCC-2998) [4]
Lenalidomide + Cyclophosphamide DCPGZMR Lenalidomide Lung adenocarcinoma (Cell Line: EKVX) [4]
Lenalidomide + Cyclophosphamide DCBL3N6 Lenalidomide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Lenalidomide + Cyclophosphamide DCOMM3T Lenalidomide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Letrozole + Cyclophosphamide DCXQ4IH Letrozole Glioblastoma (Cell Line: SNB-75) [3]
Letrozole + Cyclophosphamide DCPIVBH Letrozole Glioma (Cell Line: SF-268) [3]
Letrozole + Cyclophosphamide DCT63MH Letrozole Malignant melanoma (Cell Line: UACC62) [3]
Letrozole + Cyclophosphamide DCNF142 Letrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Letrozole + Cyclophosphamide DCD0Y8N Letrozole Invasive ductal carcinoma (Cell Line: T-47D) [5]
LIAROZOLE + Cyclophosphamide DC2PM3V LIAROZOLE Adenocarcinoma (Cell Line: HT29) [4]
LIAROZOLE + Cyclophosphamide DC7BE2H LIAROZOLE Melanoma (Cell Line: UACC-257) [4]
Mechlorethamine + Cyclophosphamide DC4TSJM Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Mechlorethamine + Cyclophosphamide DCCDJ0Z Mechlorethamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Mechlorethamine + Cyclophosphamide DCWBMH9 Mechlorethamine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Mepacrine + Cyclophosphamide DC9DAM1 Mepacrine Adenocarcinoma (Cell Line: HCT-15) [4]
Mepacrine + Cyclophosphamide DCZPOX3 Mepacrine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Mepacrine + Cyclophosphamide DCA3US8 Mepacrine Malignant melanoma (Cell Line: LOX IMVI) [4]
Nilotinib + Cyclophosphamide DCNTP5T Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [3]
Nilotinib + Cyclophosphamide DCT01XY Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Nilotinib + Cyclophosphamide DCL4DHD Nilotinib Adenocarcinoma (Cell Line: NCIH23) [4]
Nilotinib + Cyclophosphamide DCYHCN2 Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Nilotinib + Cyclophosphamide DCYAB4I Nilotinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Picoplatin + Cyclophosphamide DCI9S2C Picoplatin Astrocytoma (Cell Line: U251) [3]
Picoplatin + Cyclophosphamide DCJLIZ1 Picoplatin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Picoplatin + Cyclophosphamide DC1N6ZE Picoplatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Plicamycin + Cyclophosphamide DCBZQE6 Plicamycin Astrocytoma (Cell Line: SNB-19) [3]
Plicamycin + Cyclophosphamide DCI7H98 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [3]
Plicamycin + Cyclophosphamide DCYV5BK Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Plicamycin + Cyclophosphamide DCP9OCU Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [5]
Plicamycin + Cyclophosphamide DCHBCI0 Plicamycin Adenocarcinoma (Cell Line: DU-145) [4]
Plicamycin + Cyclophosphamide DCFWY0B Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Plicamycin + Cyclophosphamide DCSSWTS Plicamycin Melanoma (Cell Line: UACC-257) [4]
PMID28460551-Compound-2 + Cyclophosphamide DC8PYMN PMID28460551-Compound-2 Carcinoma (Cell Line: RXF 393) [5]
PMID28460551-Compound-2 + Cyclophosphamide DCVO2X9 PMID28460551-Compound-2 Amelanotic melanoma (Cell Line: M14) [4]
PMID28870136-Compound-43 + Cyclophosphamide DCXJ0Z1 PMID28870136-Compound-43 Glioblastoma (Cell Line: SNB-75) [3]
PMID28870136-Compound-43 + Cyclophosphamide DC6J4QT PMID28870136-Compound-43 Glioma (Cell Line: SF-295) [3]
PMID28870136-Compound-43 + Cyclophosphamide DCUBFAF PMID28870136-Compound-43 Carcinoma (Cell Line: RXF 393) [5]
PMID28870136-Compound-43 + Cyclophosphamide DCSK0Y1 PMID28870136-Compound-43 Adenocarcinoma (Cell Line: HCT-15) [4]
PMID28870136-Compound-43 + Cyclophosphamide DC4LL2R PMID28870136-Compound-43 Lung adenocarcinoma (Cell Line: HOP-62) [4]
PMID28870136-Compound-43 + Cyclophosphamide DC6WUJE PMID28870136-Compound-43 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Pomalidomide + Cyclophosphamide DC1DK1F Pomalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Pomalidomide + Cyclophosphamide DCL2IA5 Pomalidomide Glioma (Cell Line: SF-539) [3]
Pomalidomide + Cyclophosphamide DC0X7EJ Pomalidomide Malignant melanoma (Cell Line: UACC62) [3]
Pralatrexate + Cyclophosphamide DC1ASQS Pralatrexate Glioma (Cell Line: SF-295) [3]
Pralatrexate + Cyclophosphamide DC4ZIJN Pralatrexate Invasive ductal carcinoma (Cell Line: HS 578T) [5]
Raloxifene + Cyclophosphamide DCXLBJA Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Raloxifene + Cyclophosphamide DCL7YXY Raloxifene Glioma (Cell Line: SF-268) [3]
Raloxifene + Cyclophosphamide DC1ORTZ Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Raloxifene + Cyclophosphamide DCXRAX5 Raloxifene Adenocarcinoma (Cell Line: NCIH23) [4]
Raloxifene + Cyclophosphamide DCILEIN Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Raloxifene + Cyclophosphamide DCNXCRC Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Raloxifene + Cyclophosphamide DCGR0VE Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Raloxifene + Cyclophosphamide DCM5SJ4 Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Ruxolitinib + Cyclophosphamide DCYGXLJ Ruxolitinib Astrocytoma (Cell Line: U251) [3]
Ruxolitinib + Cyclophosphamide DCW865W Ruxolitinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Ruxolitinib + Cyclophosphamide DCV0BA7 Ruxolitinib Lung adenocarcinoma (Cell Line: EKVX) [4]
SCH 727965 + Cyclophosphamide DCMG1QU SCH 727965 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Sirolimus + Cyclophosphamide DCA7OGK Sirolimus Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Sorafenib + Cyclophosphamide DCUA28B Sorafenib Adenocarcinoma (Cell Line: HCT116) [3]
Sorafenib + Cyclophosphamide DC9BEQ7 Sorafenib Glioma (Cell Line: SF-539) [3]
Sorafenib + Cyclophosphamide DC7CLZH Sorafenib High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Sorafenib + Cyclophosphamide DCE8MPN Sorafenib Lung adenocarcinoma (Cell Line: HOP-62) [3]
Sorafenib + Cyclophosphamide DCRS75B Sorafenib Lung adenocarcinoma (Cell Line: NCI-H522) [3]
Sorafenib + Cyclophosphamide DC9VKEC Sorafenib Malignant melanoma (Cell Line: LOX IMVI) [3]
Sorafenib + Cyclophosphamide DCTNH56 Sorafenib Melanoma (Cell Line: UACC-257) [3]
Sorafenib + Cyclophosphamide DCDJNX0 Sorafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
SY-1425 + Cyclophosphamide DCL2VO0 SY-1425 Adenocarcinoma (Cell Line: DU-145) [4]
SY-1425 + Cyclophosphamide DCBCB0P SY-1425 Amelanotic melanoma (Cell Line: M14) [4]
SY-1425 + Cyclophosphamide DCDSMTI SY-1425 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
SY-1425 + Cyclophosphamide DCM3Q7F SY-1425 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Taxol + Cyclophosphamide DC4ZEP4 Taxol Renal cell carcinoma (Cell Line: UO-31) [3]
Taxol + Cyclophosphamide DCGM1DV Taxol Adenocarcinoma (Cell Line: HCT-15) [4]
TEM + Cyclophosphamide DCGGYXQ TEM Adenocarcinoma (Cell Line: OVCAR3) [4]
TEM + Cyclophosphamide DC9C321 TEM Adenocarcinoma (Cell Line: NCIH23) [4]
TEM + Cyclophosphamide DCVNZFG TEM Adenocarcinoma (Cell Line: HT29) [4]
TEM + Cyclophosphamide DCDM8N0 TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
TEM + Cyclophosphamide DCLIQ4B TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
TEM + Cyclophosphamide DCTLCFY TEM Malignant melanoma (Cell Line: UACC62) [4]
Terameprocol + Cyclophosphamide DC29E5E Terameprocol Glioma (Cell Line: SF-539) [3]
Terameprocol + Cyclophosphamide DC6HCXC Terameprocol Renal cell carcinoma (Cell Line: UO-31) [3]
Terameprocol + Cyclophosphamide DCQDNS4 Terameprocol Colon adenocarcinoma (Cell Line: COLO 205) [5]
Terameprocol + Cyclophosphamide DCUPTGJ Terameprocol Adenocarcinoma (Cell Line: HCC-2998) [4]
Terameprocol + Cyclophosphamide DC4KE3F Terameprocol Adenocarcinoma (Cell Line: HCT116) [4]
Terameprocol + Cyclophosphamide DCL35Z6 Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Terameprocol + Cyclophosphamide DCGMVHH Terameprocol Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Terameprocol + Cyclophosphamide DCRIKM8 Terameprocol Malignant melanoma (Cell Line: UACC62) [4]
Thioguanine + Cyclophosphamide DCIPJZ4 Thioguanine Chronic myelogenous leukemia (Cell Line: K-562) [3]
Thioguanine + Cyclophosphamide DCEEWLZ Thioguanine Adenocarcinoma (Cell Line: HCC-2998) [4]
Thioguanine + Cyclophosphamide DCX8SEW Thioguanine Prostate carcinoma (Cell Line: PC-3) [4]
Topotecan + Cyclophosphamide DCBIC9K Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Triapine + Cyclophosphamide DCLN1HN Triapine Adenocarcinoma (Cell Line: DU-145) [4]
Triapine + Cyclophosphamide DCJCUPK Triapine Amelanotic melanoma (Cell Line: M14) [4]
Triapine + Cyclophosphamide DCFPCTN Triapine Glioma (Cell Line: SF-268) [4]
Triapine + Cyclophosphamide DC7FN6U Triapine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Trifluridine + Cyclophosphamide DCRMQDE Trifluridine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Trifluridine + Cyclophosphamide DC0HAA7 Trifluridine Lung adenocarcinoma (Cell Line: EKVX) [4]
Uracil mustard + Cyclophosphamide DCRYSCZ Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Uracil mustard + Cyclophosphamide DCESSVD Uracil mustard Melanoma (Cell Line: SK-MEL-2) [4]
Valrubicin + Cyclophosphamide DC6HGXP Valrubicin Astrocytoma (Cell Line: U251) [3]
Vandetanib + Cyclophosphamide DCHJTZ5 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vandetanib + Cyclophosphamide DCSRJRE Vandetanib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Cyclophosphamide DCTPAU3 Vandetanib Astrocytoma (Cell Line: SNB-19) [4]
Vemurafenib + Cyclophosphamide DC4NZOD Vemurafenib Carcinoma (Cell Line: MCF7) [5]
Vemurafenib + Cyclophosphamide DC3BO8Y Vemurafenib Colon carcinoma (Cell Line: KM12) [5]
Vemurafenib + Cyclophosphamide DCCOLKH Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vemurafenib + Cyclophosphamide DCQH5N5 Vemurafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vincristine + Cyclophosphamide DCARX9G Vincristine Adenocarcinoma (Cell Line: DU-145) [3]
Vincristine + Cyclophosphamide DCTOLNK Vincristine Adenocarcinoma (Cell Line: OVCAR3) [3]
Vincristine + Cyclophosphamide DCVLHCS Vincristine Adenocarcinoma (Cell Line: HCC-2998) [3]
Vincristine + Cyclophosphamide DCETRM8 Vincristine Adenocarcinoma (Cell Line: SW-620) [3]
Vincristine + Cyclophosphamide DCTYQLK Vincristine Adenocarcinoma (Cell Line: HT29) [3]
Vincristine + Cyclophosphamide DCSAYUD Vincristine Astrocytoma (Cell Line: SNB-19) [3]
Vincristine + Cyclophosphamide DCCDF0A Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Vincristine + Cyclophosphamide DCF5JOK Vincristine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vincristine + Cyclophosphamide DC0CPV6 Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [3]
Vincristine + Cyclophosphamide DC55VAW Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Vincristine + Cyclophosphamide DCPM983 Vincristine Breast adenocarcinoma (Cell Line: MDA-MB-468) [5]
Vincristine + Cyclophosphamide DCI7N9N Vincristine Carcinoma (Cell Line: MCF7) [5]
Vincristine + Cyclophosphamide DCPITCI Vincristine Colon carcinoma (Cell Line: KM12) [5]
Vincristine + Cyclophosphamide DCG082W Vincristine Invasive ductal carcinoma (Cell Line: BT-549) [5]
Vinflunine + Cyclophosphamide DCBIOT5 Vinflunine Glioma (Cell Line: SF-539) [3]
Vinflunine + Cyclophosphamide DC5R252 Vinflunine Renal cell carcinoma (Cell Line: UO-31) [3]
Vinflunine + Cyclophosphamide DCBI0S0 Vinflunine Adenocarcinoma (Cell Line: SW-620) [4]
Vismodegib + Cyclophosphamide DC2Y06I Vismodegib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vismodegib + Cyclophosphamide DCDWTGU Vismodegib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vismodegib + Cyclophosphamide DCZGAUC Vismodegib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vismodegib + Cyclophosphamide DC72KW7 Vismodegib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 412 DrugCom(s)
125 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
ABT-888 + Cyclophosphamide DCBE5RD ABT-888 Ovarian Cancer [6]
AP1903 + Cyclophosphamide DC37J6Q AP1903 Lymphoma [7]
AP1903 + Cyclophosphamide DC7IT1W AP1903 Myeloma-Multiple [8]
Cyclophosphamide + Mycophenolate mofetil DC3C2VJ Mycophenolate mofetil Acute Myeloid Leukemia (AML) [9]
Cyclophosphamide + Docetaxel DCATK50 Docetaxel Breast Cancer [10]
Cyclophosphamide + Methotrexate DCRBM5R Methotrexate Adult Acute Myeloid Leukemia in Remission [11]
Cyclophosphamide + Mesna DC009BJ Mesna Leukemia [12]
Cyclophosphamide + Carboplatin DC04R48 Carboplatin Adult Acute Lymphoblastic Leukemia in Remission [13]
Cyclophosphamide + Etoposide DCRAUA1 Etoposide Adult Acute Lymphoblastic Leukemia in Remission [13]
Cyclophosphamide + Docetaxel DCU9D0Y Docetaxel Breast Cancer [10]
Cyclophosphamide + Fludarabine DCYPH5P Fludarabine Epidermolysis Bullosa [14]
Cyclophosphamide + Fludarabine DC1WBPB Fludarabine Melanoma [15]
Cyclophosphamide + Busulfan DC2N014 Busulfan Leukemia, Myeloid, Chronic [16]
Cyclophosphamide + Paclitaxel DC4X6FF Paclitaxel Stage IA Breast Cancer [17]
Cyclophosphamide + Lenalidomide DC7TDVR Lenalidomide Intraocular Melanoma [18]
Cyclophosphamide + Etoposide DC9NZXL Etoposide Anaplastic Large Cell Lymphoma [19]
Cyclophosphamide + Vinorelbine DCAB5GY Vinorelbine Adult Rhabdomyosarcoma [20]
Cyclophosphamide + Methotrexate DCB1Z2I Methotrexate Mucopolysaccharidosis [21]
Cyclophosphamide + Cytarabine DCCGLTU Cytarabine Leukemia [22]
Cyclophosphamide + Docetaxel DCD72UI Docetaxel Breast Cancer [23]
Cyclophosphamide + Cytarabine DCDSOPX Cytarabine Acute Lymphoblastic Leukemia [24]
Cyclophosphamide + Lenalidomide DCDYWB2 Lenalidomide Adenocarcinoma of the Prostate [25]
Cyclophosphamide + Cyclosporin A DCIJ8RT Cyclosporin A Aplastic Anemia [26]
Cyclophosphamide + Oxaliplatin DCIJBVF Oxaliplatin Pancreatic Cancer [27]
Cyclophosphamide + Clofarabine DCJJ5CN Clofarabine Burkitt's Lymphoma [28]
Cyclophosphamide + Plerixafor DCM624E Plerixafor Refractory Multiple Myeloma [29]
Cyclophosphamide + Methotrexate DCNF8YP Methotrexate Breast Cancer [30]
Cyclophosphamide + Mycophenolate mofetil DCQ3HNZ Mycophenolate mofetil Systemic Scleroderma [31]
Cyclophosphamide + Fludarabine DCQFTOE Fludarabine Follicular Lymphoma [32]
Cyclophosphamide + Capecitabine DCQZLUL Capecitabine Breast Cancer [33]
Cyclophosphamide + Busulfan DCUCBNI Busulfan Leukemia [22]
Cyclophosphamide + Etoposide DCWWWEK Etoposide Recurrent Adult Burkitt Lymphoma [34]
Cyclophosphamide + Celecoxib DCY7CF7 Celecoxib Fallopian Tube Cancer [35]
Cyclophosphamide + Mycophenolate mofetil DC65XI3 Mycophenolate mofetil Cutaneous T-Cell Non-Hodgkin Lymphoma [36]
Cyclophosphamide + Mycophenolate mofetil DC8O9B9 Mycophenolate mofetil Hodgkin's Lymphoma [37]
Cyclophosphamide + Mycophenolate mofetil DC8UWX2 Mycophenolate mofetil Acute Lymphoblastic Leukemia [38]
Cyclophosphamide + Mycophenolate mofetil DCDT6YJ Mycophenolate mofetil Graft Versus Host Disease [39]
Cyclophosphamide + Celecoxib DCQW1WE Celecoxib Neuroblastoma [40]
Cyclophosphamide + Mycophenolate mofetil DCXVJKR Mycophenolate mofetil Accelerated Phase Chronic Myelogenous Leukemia [41]
Cyclophosphamide + Cyclosporin A DC0J5JV Cyclosporin A Acute Myelogenous Leukemia [42]
Cyclophosphamide + Methotrexate DC3JOEX Methotrexate Adult Acute Lymphoblastic Leukemia in Remission [43]
Cyclophosphamide + Etoposide DC3YMDJ Etoposide Adult Grade III Lymphomatoid Granulomatosis [44]
Cyclophosphamide + Everolimus DC7F9O2 Everolimus Liver Transplant [45]
Cyclophosphamide + Methoxsalen DC877LM Methoxsalen Leukemia [46]
Cyclophosphamide + Etoposide DCC4UBO Etoposide Lymphoma [47]
Cyclophosphamide + Methotrexate DCDS5IT Methotrexate Breast Cancer Female [48]
Cyclophosphamide + Paclitaxel DCHXAOZ Paclitaxel Breast Cancer [49]
Cyclophosphamide + Fludarabine DCLZQC3 Fludarabine Acute Lymphoblastic Leukemia, in Relapse [50]
Cyclophosphamide + Mycophenolate mofetil DCQAZQR Mycophenolate mofetil Hematologic Malignancies [51]
Cyclophosphamide + Mycophenolate mofetil DCQYR1O Mycophenolate mofetil Aplastic Anemia [52]
Cyclophosphamide + Lenalidomide DCUG6NF Lenalidomide Refractory Multiple Myeloma [53]
Cyclophosphamide + Topotecan DCCDWAH Topotecan Neoplasm [54]
Cyclophosphamide + Letrozole DCESL59 Letrozole Breast Cancer [55]
Cyclophosphamide + LY2606368 DCHZGHS LY2606368 Brain Tumor [56]
Cyclophosphamide + Docetaxel DCO7SQF Docetaxel Neutropenia [57]
Cyclophosphamide + Testosterone cypionate DCWHYLB Testosterone cypionate Prostate Cancer [58]
Dactinomycin + Cyclophosphamide DC62YHJ Dactinomycin Rhabdomyosarcoma [59]
Dexamethasone + Cyclophosphamide DCNPMP5 Dexamethasone Hemophagocytic Syndrome [60]
Eribulin + Cyclophosphamide DC08UFK Eribulin HER2 Negative Breast Cancer [61]
Eribulin + Cyclophosphamide DCXA0SI Eribulin Malignant Solid Tumour [62]
Imiquimod + Cyclophosphamide DCB99EA Imiquimod Breast Cancer [63]
Imiquimod + Cyclophosphamide DCKTYHC Imiquimod Adenocarcinoma of the Prostate [64]
Ixabepilone + Cyclophosphamide DCSR81T Ixabepilone Breast Cancer [65]
Omeprazole + Cyclophosphamide DCRV9OK Omeprazole Breast Neoplasm [66]
Pentostatin + Cyclophosphamide DC7UH9A Pentostatin Chronic Lymphocytic Leukemia [67]
Pentostatin + Cyclophosphamide DCJ47KC Pentostatin Mesothelioma [68]
Pentostatin + Cyclophosphamide DCW64MQ Pentostatin Leukemia [69]
Cyclophosphamide + Carboplatin DC66JRG Carboplatin Triple Negative Breast Cancer [70]
Cyclophosphamide + Dexrazoxane DC7GMDM Dexrazoxane Ewing's Sarcoma [71]
Cyclophosphamide + Mycophenolate mofetil DC9THKQ Mycophenolate mofetil Acute Myeloid Leukemia [72]
Cyclophosphamide + Methotrexate DCACZHQ Methotrexate Adult Acute Myeloid Leukemia in Remission [73]
Cyclophosphamide + Methylprednisolone DCAOIHS Methylprednisolone Fanconi Anemia [74]
Cyclophosphamide + Mycophenolate mofetil DCB9RDM Mycophenolate mofetil Accelerated Phase Chronic Myelogenous Leukemia [75]
Cyclophosphamide + Carboplatin DCBXO27 Carboplatin Brain and Central Nervous System Tumors [76]
Cyclophosphamide + Carboplatin DCCVM27 Carboplatin Triple-Negative Invasive Breast Carcinoma [77]
Cyclophosphamide + Etoposide DCIIRP0 Etoposide AIDS-related Diffuse Large Cell Lymphoma [78]
Cyclophosphamide + Aspirin DCMFLGF Aspirin Colo-rectal Cancer [79]
Cyclophosphamide + Ifosfamide DCPUEJO Ifosfamide Sarcoma [80]
Cyclophosphamide + Etoposide DCU9D5P Etoposide Lymphoma [81]
Cyclophosphamide + Mycophenolate mofetil DCUB5EU Mycophenolate mofetil Accelerated Phase Chronic Myelogenous Leukemia [82]
Cyclophosphamide + Mycophenolate mofetil DCV762J Mycophenolate mofetil Myelodysplastic Syndrome [83]
Cyclophosphamide + Cyclosporin A DCV8IFB Cyclosporin A Chronic Granulomatous Disease [84]
Cyclophosphamide + Mycophenolate mofetil DCZEYXM Mycophenolate mofetil Acute Myeloid Leukemia [85]
Cyclophosphamide + Sirolimus DC3CAQE Sirolimus Acute Lymphoblastic Leukemia [86]
Cyclophosphamide + Carboplatin DC3JKQJ Carboplatin Lung Cancer [87]
Cyclophosphamide + Mycophenolate mofetil DC9WCRN Mycophenolate mofetil Acute Leukemia [88]
Cyclophosphamide + Methylprednisolone DCBAHA8 Methylprednisolone Kidney Transplantation [89]
Cyclophosphamide + Clofarabine DCCBX4E Clofarabine Acute Myeloid Leukemia [90]
Cyclophosphamide + Tacrolimus DCCFQRU Tacrolimus Graft Vs Host Disease [91]
Cyclophosphamide + Etoposide DCCX6PZ Etoposide Lymphoma [92]
Cyclophosphamide + Methylprednisolone DCECI3I Methylprednisolone Lymphoproliferative Disorder [93]
Cyclophosphamide + Gemcitabine DCENLKG Gemcitabine Acute Lymphoblastic Leukemia, Adult [94]
Cyclophosphamide + Cyclosporin A DCI2UFM Cyclosporin A Chronic Myelogenous Leukemia [95]
Cyclophosphamide + Mycophenolate mofetil DCJP2JH Mycophenolate mofetil Hematologic Malignancy [96]
Cyclophosphamide + Mycophenolate mofetil DCKOQ5H Mycophenolate mofetil Hematological Malignancies [97]
Cyclophosphamide + Carboplatin DCN7EZ7 Carboplatin Breast Cancer [98]
Cyclophosphamide + Topotecan DCNHQ9W Topotecan Neuroblastoma [99]
Cyclophosphamide + Etoposide DCQG4P0 Etoposide Non-Hodgkin Lymphoma [100]
Cyclophosphamide + Thiotepa DCQY0XW Thiotepa Lymphoma [101]
Cyclophosphamide + Mycophenolate mofetil DCR907N Mycophenolate mofetil Hematopoietic and Lymphoid Cell Neoplasm [102]
Cyclophosphamide + Methotrexate DCVLUL9 Methotrexate Aplastic Anemia [103]
Cyclophosphamide + Mycophenolate mofetil DC8LDFD Mycophenolate mofetil Hematopoietic/Lymphoid Cancer [104]
Cyclophosphamide + Thiotepa DCH9LKH Thiotepa Leukemia, Myeloid, Acute [105]
Cyclophosphamide + Bortezomib DCHT595 Bortezomib Adult-onset Immunodeficiency [106]
Cyclophosphamide + Exemestane DCZABKE Exemestane Metastatic Beast Cancer [107]
Dexamethasone + Cyclophosphamide DC4BSYP Dexamethasone Leukemia [108]
Dexamethasone + Cyclophosphamide DC52BGE Dexamethasone Relapse/Refractory Multiple Myeloma [109]
Dexamethasone + Cyclophosphamide DC6IL7L Dexamethasone Leukemia [108]
Dexamethasone + Cyclophosphamide DC7KVXW Dexamethasone Multiple Myeloma [110]
Dexamethasone + Cyclophosphamide DCM234Y Dexamethasone Primary Systemic Amyloidosis [111]
Dexamethasone + Cyclophosphamide DCXBUN3 Dexamethasone Stage I Multiple Myeloma [112]
Dexamethasone + Cyclophosphamide DCYABFL Dexamethasone Amyloidosis [113]
Dexamethasone + Cyclophosphamide DCYPCFI Dexamethasone Multiple Myeloma in Relapse [114]
Lapatinib + Cyclophosphamide DCJVI8F Lapatinib Breast Cancer [115]
Omeprazole + Cyclophosphamide DCXJHN7 Omeprazole Squamous Cell Carcinoma of the Oral Cavity [116]
Ruxolitinib + Cyclophosphamide DCUVFNT Ruxolitinib Graft-versus-host Disease [117]
Cyclophosphamide + Methotrexate DC2HDW8 Methotrexate B-cell Childhood Acute Lymphoblastic Leukemia [118]
Cyclophosphamide + Etoposide DCSZO6I Etoposide Brain Cancer [119]
Cyclophosphamide + Vincristine DCEEEZI Vincristine Untreated Childhood Medulloblastoma [120]
Cyclophosphamide + Docetaxel DCSD3XA Docetaxel Breast Cancer [121]
Cyclophosphamide + Thiotepa DCW552D Thiotepa Breast Cancer [122]
Cyclophosphamide + Methylprednisolone DCHN54L Methylprednisolone Glomerulonephritis, Membranous [123]
Dexamethasone + Cyclophosphamide DCJSXFV Dexamethasone Multiple Myeloma [124]
Dexamethasone + Cyclophosphamide DCPVNZ9 Dexamethasone Multiple Myeloma [125]
Cyclophosphamide + Methylprednisolone DC576S1 Methylprednisolone Lupus Nephritis [126]
------------------------------------------------------------------------------------
⏷ Show the Full List of 125 DrugCom(s)

References

1 Cyclophosphamide FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 ClinicalTrials.gov (NCT01306032) Phase II ABT-888 With Cyclophosphamide
7 ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
8 ClinicalTrials.gov (NCT03958656) T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
9 ClinicalTrials.gov (NCT01962636) Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
10 ClinicalTrials.gov (NCT00432172) Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
11 ClinicalTrials.gov (NCT00445744) Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
12 ClinicalTrials.gov (NCT00578461) T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE
13 ClinicalTrials.gov (NCT00536601) High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
14 ClinicalTrials.gov (NCT00478244) Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
15 ClinicalTrials.gov (NCT00001832) Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
16 ClinicalTrials.gov (NCT00176930) Stem Cell Transplant for Hematological Malignancy
17 ClinicalTrials.gov (NCT01106898) Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
18 ClinicalTrials.gov (NCT00482911) Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
19 ClinicalTrials.gov (NCT00073918) Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
20 ClinicalTrials.gov (NCT01222715) Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
21 ClinicalTrials.gov (NCT01238328) Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis
22 ClinicalTrials.gov (NCT00054327) Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
23 ClinicalTrials.gov (NCT00493870) TAC Versus TC for Adjuvant Breast Cancer
24 ClinicalTrials.gov (NCT00368355) T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
25 ClinicalTrials.gov (NCT01093183) Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
26 ClinicalTrials.gov (NCT01193283) Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
27 ClinicalTrials.gov (NCT01595321) Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
28 ClinicalTrials.gov (NCT00412243) Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients
29 ClinicalTrials.gov (NCT01074060) Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
30 ClinicalTrials.gov (NCT00022516) Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer
31 ClinicalTrials.gov (NCT01047072) Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
32 ClinicalTrials.gov (NCT01303887) A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
33 ClinicalTrials.gov (NCT00107276) S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
34 ClinicalTrials.gov (NCT00002649) Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
35 ClinicalTrials.gov (NCT00538031) Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
36 ClinicalTrials.gov (NCT02548468) Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma
37 ClinicalTrials.gov (NCT01342289) Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
38 ClinicalTrials.gov (NCT00686556) Total Marrow Irradiation for Refractory Acute Leukemia
39 ClinicalTrials.gov (NCT00376519) Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
40 ClinicalTrials.gov (NCT02030964) N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
41 ClinicalTrials.gov (NCT00343798) A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
42 ClinicalTrials.gov (NCT00303667) Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
43 ClinicalTrials.gov (NCT02122081) Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
44 ClinicalTrials.gov (NCT01959477) Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
45 ClinicalTrials.gov (NCT03577431) Liver Transplantation With Tregs at MGH
46 ClinicalTrials.gov (NCT00005092) Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
47 ClinicalTrials.gov (NCT00569985) Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
48 ClinicalTrials.gov (NCT03518242) Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer
49 ClinicalTrials.gov (NCT03356860) Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.
50 ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
51 ClinicalTrials.gov (NCT00429143) A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
52 ClinicalTrials.gov (NCT00354419) Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
53 ClinicalTrials.gov (NCT00112827) Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
54 ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT04895761) Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
56 ClinicalTrials.gov (NCT04023669) Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
57 ClinicalTrials.gov (NCT04187898) Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
58 ClinicalTrials.gov (NCT02995330) Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
59 ClinicalTrials.gov (NCT06023641) Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
60 ClinicalTrials.gov (NCT05936086) A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
61 ClinicalTrials.gov (NCT01527487) Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
62 ClinicalTrials.gov (NCT01554371) Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
63 ClinicalTrials.gov (NCT01421017) Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
64 ClinicalTrials.gov (NCT02234921) Pilot Study of DRibble Vaccine for Prostate Cancer Patients
65 ClinicalTrials.gov (NCT00866905) Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer
66 ClinicalTrials.gov (NCT02950259) Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
67 ClinicalTrials.gov (NCT01024010) Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
68 ClinicalTrials.gov (NCT01362790) SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
69 ClinicalTrials.gov (NCT00074282) Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
70 ClinicalTrials.gov (NCT04771871) MicroRNA Profiles in Triple Negative Breast Cancer
71 ClinicalTrials.gov (NCT00038142) Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
72 ClinicalTrials.gov (NCT02566304) Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
73 ClinicalTrials.gov (NCT00005940) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission
74 ClinicalTrials.gov (NCT00258427) Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
75 ClinicalTrials.gov (NCT00049504) Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
76 ClinicalTrials.gov (NCT00003846) Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors
77 ClinicalTrials.gov (NCT02670109) Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients
78 ClinicalTrials.gov (NCT01775475) Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
79 ClinicalTrials.gov (NCT04534218) Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
80 ClinicalTrials.gov (NCT00072280) Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
81 ClinicalTrials.gov (NCT00002941) Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
82 ClinicalTrials.gov (NCT01175785) Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
83 ClinicalTrials.gov (NCT02556931) Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
84 ClinicalTrials.gov (NCT00578643) Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
85 ClinicalTrials.gov (NCT00309842) Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
86 ClinicalTrials.gov (NCT03246906) Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
87 ClinicalTrials.gov (NCT00828009) BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell LungCancer That Cannot Be Removed by Surgery. U.S. National Institutes of Health.
88 ClinicalTrials.gov (NCT02208037) Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
89 ClinicalTrials.gov (NCT00801632) Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
90 ClinicalTrials.gov (NCT01677949) Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
91 ClinicalTrials.gov (NCT05621759) Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
92 ClinicalTrials.gov (NCT00345865) Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
93 ClinicalTrials.gov (NCT00066469) Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
94 ClinicalTrials.gov (NCT03339700) Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia
95 ClinicalTrials.gov (NCT00378534) Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
96 ClinicalTrials.gov (NCT01341301) Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
97 ClinicalTrials.gov (NCT01349101) A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
98 ClinicalTrials.gov (NCT00429182) Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
99 ClinicalTrials.gov (NCT00601003) Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
100 ClinicalTrials.gov (NCT03125642) Auto Stem Cell Transplant for Lymphoma Patients
101 ClinicalTrials.gov (NCT02049580) Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas
102 ClinicalTrials.gov (NCT03032783) A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
103 ClinicalTrials.gov (NCT00343785) Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
104 ClinicalTrials.gov (NCT01982682) Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
105 ClinicalTrials.gov (NCT05565105) CD34+ Transplants for Leukemia and Lymphoma
106 ClinicalTrials.gov (NCT03103555) Treatment of Adult-Onset Immunodeficiency With Bortezomib
107 ClinicalTrials.gov (NCT01963481) Exemestane and Cyclophosphamide for Metastatic Breast Cancer
108 ClinicalTrials.gov (NCT00630565) Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
109 ClinicalTrials.gov (NCT02985333) Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
110 ClinicalTrials.gov (NCT02467010) Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance
111 ClinicalTrials.gov (NCT01072773) Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
112 ClinicalTrials.gov (NCT01706666) Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
113 ClinicalTrials.gov (NCT00607581) Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
114 ClinicalTrials.gov (NCT02176213) Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
115 ClinicalTrials.gov (NCT00841828) Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
116 ClinicalTrials.gov (NCT02609386) IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
117 ClinicalTrials.gov (NCT05622318) De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
118 ClinicalTrials.gov (NCT00382109) Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
119 ClinicalTrials.gov (NCT01014767) Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
120 ClinicalTrials.gov (NCT00085735) Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
121 ClinicalTrials.gov (NCT00129935) EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
122 ClinicalTrials.gov (NCT00002836) Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer
123 ClinicalTrials.gov (NCT03018535) Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy
124 ClinicalTrials.gov (NCT02362165) CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma
125 ClinicalTrials.gov (NCT03440411) Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
126 ClinicalTrials.gov (NCT02645565) Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis